Ignite Creation Date:
2025-12-24 @ 11:37 PM
Ignite Modification Date:
2025-12-25 @ 9:27 PM
Study NCT ID:
NCT03807856
Status:
TERMINATED
Last Update Posted:
2022-09-01
First Post:
2019-01-15
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Treating Acute Pancreatitis With Dabigatran, a Pilot Study
Sponsor:
Mayo Clinic
Organization:
Study Overview
Official Title:
Treating Acute Pancreatitis With Dabigatran, a Pilot Study
Status:
TERMINATED
Status Verified Date:
2022-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Difficult recruitment
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Researchers are studying the safety and efficacy of Dabigatran in the treatment of acute pancreatitis.
Detailed Description:
Subjects with acute pancreatitis who meet the inclusion and exclusion criteria for the study will be recruited. Subjects will be randomized to receive either Dabigatran 150mg daily for three days or standard treatment. Vital signs, CBC, inflammatory markers and BMP, and bleeding complications will be evaluated daily for the next 7 days of until discharge whichever is sooner.
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: